free radical, is the product of superoxide anion and nitric oxide (NO). Endothelium-derived NO is an important endogenous mediator of cerebral blood flow and cerebrovascular protection. 6, 7 In the early phases of ischemic stroke, endothelium-derived NO acts as a neuroprotective with its vasodilator effect, but in the later phases of ischemic stroke, the overproduction of NO by induced and neuronal NO synthases results in elevated levels of peroxynitrite, which ultimately causes cellular injury. 8 Brain is particularly sensitive to oxidative stress because of its high oxygen demand, lipid content, and chemical reaction involving dopamine oxidation and glutamate. 9 The hazardous effect of oxidative stress is increased in the hyperglycemic state, 10 as it is evidenced that hyperglycemia in the acute period of stroke is a marker of poor prognosis. 11 Although many mechanisms have been proposed to elucidate the cause of the poor prognosis, we suggest that the I schemic stroke is a common and devastating disorder that often results in death or permanent disability. Occlusion of the cerebral vessels causes an irreversible and fatal damage of the affected cerebral tissue; however, the reperfusion of the same area may also be detrimental. 1 Free radical formation is the pivotal mechanism of neuronal injury of ischemic and reperfused brain tissue. 2 In healthy individuals, antioxidant activity counterbalances free radical production, but in the case of ischemia, the balance between reactive oxygen species and antioxidant activity is shifted toward free radicals, causing oxidative stress. 3-5 Peroxynitrite, a Free radical formation is the pivotal mechanism of neuronal injury of ischemic and reperfused brain tissue. In healthy individuals, antioxidant activity counterbalances free radical production, but in the case of ischemia, the balance between reactive oxygen species and antioxidant activity is shifted toward free radicals, causing oxidative stress. The aim of this study is to assess total antioxidant capacity (TAC) and oxidative stress in diabetic and nondiabetic acute stroke patients with 2 different stroke subtypes: large and small vessel disease stroke. Sixty-five acute ischemic stroke patients (29 diabetic and 36 nondiabetic) and 20 age-matched healthy control subjects were recruited in the study. Plasma TAC and nitric oxide (NO) metabolite levels (nitrite and nitrate) were measured by enzyme-linked immunosorbent assay. The subtypes of stroke were defined according to Trial of Org 10172 in Acute Stroke Treatment criteria. The main findings of this study are that the TAC and NO levels were significantly higher in diabetic acute stroke patients than in nondiabetic patients and control cases (P < .001 and P < .001, respectively). The TAC and NO levels were higher also in nondiabetic stroke patients than in controls, but the difference did not reach any significance. No difference was found between NO and TAC levels in large and small vessel stroke subtypes of diabetic and nondiabetic patients. The authors conclude that oxidative stress and counterbalancing antioxidant capacity are more pronounced in diabetic acute stroke patients than in nondiabetic acute stroke patients.
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Materials and Methods
Sixty-five acute ischemic stroke patients (29 diabetic and 36 nondiabetic), who were admitted within 24 hours from the onset of symptoms, were enrolled in the study. The control group consisted of 20 age-matched healthy individuals with no known history of stroke, cardiovascular disease, diabetes mellitus, and any other metabolic disease. On admission, all patients underwent full neurological examination and vascular risk factors, such as hypertension, diabetes, and smoking, were noted. Blood pressure levels, lipid profiles, and fasting glucose levels of patients were recorded by a standardized protocol. According to Trial of Org 10172 in Acute Stroke Treatment criteria, stroke subtypes were determined as large artery disease and small artery disease. 12 The study was approved by the local ethics committee, and all patients gave their informed consent to participate in the study.
Venous blood samples were collected from an antecubital vein without using tourniquet on admission (within 24 hours after the onset of stroke). Fasting glucose levels and lipid parameters were measured the day after the admission. Samples were centrifuged within 15 minutes at 3000 rpm for 10 minutes, and the supernatant plasma samples were transferred to polypropylene tubes at −80°C until assays. Fasting serum glucose level was measured using glucose oxidase technique (Beckman Coulter LX20; Beckman-Coulter Inc, Fullerton, CA). Spectrophotometric method (Beckman Coulter LX20) was used to measure triglyceride, total cholesterol, and high-density lipoprotein cholesterol levels. Low-density lipoprotein cholesterol level was calculated according to Friedewald formula.
Total antioxidant capacity (Cayman, Ann Arbor, MI) was measured by commercially available enzyme-linked immunosorbent assay. Levels of nitrite (NO 2 -) and nitrate (NO 2 -) to which NO is oxidized were measured by enzyme-linked immunosorbent assay (MBL, Woburn, MA). Both the parameters were determined according to the manufacturer's instructions.
Statistical Analysis
All statistical analyses were performed using SPSS 11.5 software for Windows. Data were expressed as mean ± standard deviation, and categorical variables were compared by using a χ 2 test. The normality of the distribution of all variables was assessed by Kolmogorov-Smirnov test. Differences in clinical and laboratory parameters among the 3 groups were analyzed by analysis of variance and Kruskal-Wallis test. If the analysis of variance indicated significant difference, post hoc Scheffe's multiple comparison procedure was used to determine between-groups differences. In addition, analyses of the differences in NO and TAC levels according to the 2 stroke subtypes were done by Student's t test and Mann-Whitney test. P values <.05 were considered statistically significant. Regarding the variables correlating with NO and TAC, the association was tested using multiple analysis of covariance to adjust for the confounding variables affecting the association. Possible confounds included hypertension, smoking habit, hyperlipidemia, and previous stroke history.
Results
The main characteristics of all study subjects are presented in Table 1 . There was no difference among the 3 groups regarding age, gender, hyperlipidemia, smoking, and history of previous stroke. Systolic blood pressure was significantly higher in diabetic and nondiabetic stroke patients than in control subjects (P < .01 and P < .001, respectively). Diastolic blood pressure was higher in nondiabetic stroke patients than in controls (P < .05). The difference in diastolic blood pressure between the diabetic and nondiabetic patients was insignificant. The distribution of large and small vessel disease in the 2 patient groups did not show any difference.
TAC and NO levels were significantly higher in diabetic acute stroke patients than in nondiabetic patients and control cases (P < .001 and P < .001, respectively). TAC and NO levels were also higher in nondiabetic stroke patients than in controls, but the difference did not reach any significance. After adjusting for the relevant confounding variables, TAC and NO levels still remained significantly high in the diabetic stroke group (P < .001 and P < .01, respectively). There was also no significant difference between the NO and TAC levels among both LVD and SVD stroke subtypes in diabetic and nondiabetic patient groups (Figures 1 and 2 ).
Discussion
The main findings of the present study are that the NO and TAC levels were higher in diabetic acute ischemic stroke patients than in nondiabetic stroke and control cases. It is well-known that NO regulates cerebral vasodilatation and blood flow, and its production is under the control of NO synthase activity. We suggest that high NO levels are the reflection of increased NO production and oxidative stress in cerebral ischemia. Several experimental and patient-based studies revealed inconsistent NO results in acute stroke. Supporting our data, Seneş et al 13 reported high NO levels in acute ischemic stroke patients. Additionally, an increase in NO levels was shown in the subacute period (24-48 hours after the occlusion of cerebral arteries) of focal cerebral ischemia in rats. 14 The increase was attributed to the subacute glial activation and intracerebral migration of macrophages. These cells have subacutely synthesized inducible NO synthase activity that generates large quantities of NO. 15 Gümüştaş et al 16 demonstrated that elevation of NO levels was present in rats with ischemia-reperfusion injury, but more prominent in those that were hyperglycemic. In contrast, Nanetti et al 17 found lower plasma NO but higher peroxynitrite levels in stroke patients than in controls. They elucidated their findings with the probable reaction of NO with superoxide anion, which resulted in the increase in peroxynitrite levels. Regarding the stroke subtypes, they additionally reported higher NO levels in atherotrombotic stroke than in lacunar acute ischemic stroke. Similarly, it has been reported that plasma NO levels were lower not only in ischemic but also in hemorrhagic stroke patients. 18 Striking high NO levels in diabetic stroke patients suggest a cumulative effect of both diseases on oxidative stress. In accord with our study, Gümüştaş et al 16 found high NO levels in hyperglycemic rats with cerebral ischemia-reperfusion injury. Hyperglycemia increases reactive oxygen species, causes lactic acid accumulation in mitochondria, and superoxide anion formation during reperfusion. 19 Aggravated oxidative stress has been implicated as the cause of the impairment of the blood-brain barrier, the increase in edema, and the deterioration of neurological symptoms in hyperglycemic conditions. 10 It is evidenced that hyperglycemia is a marker of poor prognosis in stroke. 11, 20 In a recent randomized pilot study, aggressive treatment of hyperglycemia in diabetic acute ischemic Oxidative Stress and TAC in Stroke Patients / Guldiken et al 697 NOTES: NS = nonsignificant; SBP = systolic blood pressure; DBP = diastolic blood pressure; NO = nitric oxide; TAC = total antioxidant capacity; LVD = large vessel disease; SVD = small vessel disease. a For SBP, there is a comparison between patients and control subjects (P < .01) and a comparison between nondiabetic patients and control subjects (P < .001). b For DBP, there is a comparison between nondiabetic patients and control subjects (P < .05). c For NO and TAC, there is a comparison between diabetic stroke patients and control subjects (P < .001) and a comparison between diabetic and nondiabetic patients (P < .001).
stroke demonstrated nonsignificantly better outcome scores at the end of the third month when compared with mildly treated patients. 21 Measurement of TAC, used in present study, is an easy and reliable method. Water-soluble and lipidsoluble antioxidants are not separated in this protocol, thus the combined antioxidant activities of all its constituents, including vitamins, proteins, lipids, gluthatione, and uric acid, are assessed. TAC should be interpreted together with oxidative stress because the measurement reflects outcomes in a dynamic system. An increased antioxidant capacity in plasma may not necessarily be a desirable condition if it reflects a response to increased oxidative stress. Similarly, a decrease in plasma antioxidant capacity may not necessarily be an undesirable condition if the measurement reflects decreased production of reactive species. 22 In the present study, the TAC levels of the nondiabetic stroke patients did not show any difference from that of controls, whereas it was significantly higher in diabetic stroke patients than in the other 2 groups. Regarding the high NO levels in the diabetic group, we suggest that the increase in TAC was a reaction to increased oxidative stress. In contrast, Gariballa et al 23 found lower TAC levels in acute ischemic patients than in control subjects, but the oxidative stress of the patients was not assessed.
Some other studies that investigated antioxidant status in stroke used individual antioxidant tests. Cherubini et al 24 reported that vitamin A, uric acid, superoxide dismutase, and vitamin C levels decreased in stroke patients and that early poor outcome was associated with higher vitamin A and uric acid levels, but with lower superoxide dismutase and vitamin C levels when compared with those who remained functionally stable. In another study, thiobarbituric acid-reactive substances were found to be high in ischemic stroke, whereas vitamin E and cholesteroladjusted carotenoids were lower, but selenium, total sulfhydryl group, and protein carbonyls were indifferent among stroke and control cases. 25 Another finding of our study was that TAC and NO levels were not different in large vessel disease and small vessel disease strokes in both diabetic and nondiabetic stroke groups. Leinonen et al 26 measured the cerebral infarct volume with magnetic resonance imaging and found significantly low plasma TAC levels in patients with large infarct volume and poor prognosis. But the study by Leinonen et al 26 and our study consisted of small numbers of patients to provide any conclusive argument. Larger studies are needed to assess the relationship of stroke subtypes with antioxidant capacity.
In conclusion, we determined that diabetes mellitus brings an additive oxidative stress load to acute ischemic stroke patients. These patients need to be managed carefully with regard to their poor prognosis. We consider that high TAC levels in diabetic stroke patients render the antioxidant supplementation useless at least for the acute-phase (24 hours) treatment of stroke. Oxidative stress and TAC in the later periods of acute ischemic stroke need to be explored in further studies.
